We are live on ! Find out more
GLUE icon

Monte Rosa Therapeutics
GLUE

53 hedge funds and large institutions have $742M invested in Monte Rosa Therapeutics in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 10

2.9% more ownership

Funds ownership: 75.23% → 78.13% (+2.9%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

2% less capital invested

Capital invested by funds: $759M → $742M (-$17.4M)

5% less funds holding

Funds holding: 56 → 53 (-3)

18% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 11

Holders
53
Holders Change
-3
Holders Change %
-5.36%
% of All Funds
0.82%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
24
Reduced
10
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$20.9M
2
BlackRock
BlackRock
New York
+$5.97M
3
Jennison Associates
Jennison Associates
New York
+$4.89M
4
TD Asset Management
TD Asset Management
Ontario, Canada
+$1.96M
5
E
Ergoteles
New York
+$1.56M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$3.91M
2
SFM
Sphera Funds Management
Israel
-$2.67M
3
CAM
Cormorant Asset Management
Massachusetts
-$2.09M
4
WP
Woodline Partners
California
-$1.8M
5
CCM
CAAS Capital Management
New York
-$1.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ensign Peak Advisors
51
Ensign Peak Advisors
Utah
$5K +$5.03K +240 New
MIFH
52
Migdal Insurance & Financial Holdings
Israel
$3K -$2.64K -126 -50%
Daiwa Securities Group
53
Daiwa Securities Group
Japan
$3K +$2.85K +136 New
Millennium Management
54
Millennium Management
New York
– -$3.91M -175,445 Closed
SFM
55
Sphera Funds Management
Israel
– -$2.67M -119,647 Closed
CCM
56
CAAS Capital Management
New York
– -$1.11M -50,000 Closed
LGM
57
Logos Global Management
California
– -$1.11M -50,000 Closed
SCM
58
Soleus Capital Management
Connecticut
– -$557K -25,000 Closed
GCM
59
Ghisallo Capital Management
Massachusetts
– -$334K -15,000 Closed
CSS
60
Cubist Systematic Strategies
Connecticut
– -$239K -10,731 Closed
RhumbLine Advisers
61
RhumbLine Advisers
Massachusetts
– -$206K -9,233 Closed
MIM
62
MetLife Investment Management
New Jersey
– -$106K -4,756 Closed
MLICM
63
Metropolitan Life Insurance Company (MetLife)
New York
– -$80.2K -3,598 Closed
PSC
64
Piper Sandler & Co
Minnesota
– -$51K -2,300 Closed
1 2
3

GLUE Hedge Fund Activity: Q4 2021 in Review

53 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q4 2021, worth a combined $742M — down 2.3% from $759M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of GLUE and 9 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 24 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $20.9M. The largest seller was Millennium Management, exiting entirely with an estimated $3.91M sold.

  • 53 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q4 2021, down from 56 in Q3 2021.
  • Funds reported $742M of Monte Rosa Therapeutics stock for Q4 2021, down 2.3% quarter-over-quarter.
  • 9 funds opened new Monte Rosa Therapeutics positions in Q4 2021 and 11 closed out, a net change of -2 holders.
  • The largest Monte Rosa Therapeutics buyer in Q4 2021 was T. Rowe Price Associates, an estimated $20.9M added.
  • The largest Monte Rosa Therapeutics seller in Q4 2021 was Millennium Management, an estimated $3.91M sold.

Based on aggregated 13F filings for Q4 2021.